IL17A and cancer: In the presence of PRO, the level of IL-17 decreasedby 45% in the PBMCs of healthy controls(p<0.001) and decreased 20% in TILs (p<0.001),but there was no alteration in cancer patients' PBMCs(Fig 3C).